Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy

Chiara De Waure, Stefano Capri, Maria Assunta Veneziano, Maria Lucia Specchia, Chiara Cadeddu, Francesco Di Nardo, Anna Maria Ferriero, Francesca Gennari, Colette Hamilton, Agostino Mancuso, Gianluigi Quaranta, Matteo Raponi, Luca Valerio, Gianfranco Gensini, Walter Ricciardi

Research output: Contribution to journalArticlepeer-review

Abstract

Abstract Objectives To develop a comparative, cost-effectiveness, and budget impact analysis of Therakos online extracorporeal photopheresis (ECP) compared with the main alternatives used for the treatment of steroid-refractory/resistant chronic graft-versus-host disease (cGvHD) in Italy. Methods The current therapeutic pathway was identified by searching medical databases and from the results of a survey of practice in Italian clinical reference centers. A systematic review was performed to evaluate the efficacy and safety of second-line alternatives. Budget impact and cost-effectiveness analyses were performed from the Italian National Health Service perspective over a 7-year time horizon through the adaption of a Markov model. The following health states were considered: complete and partial response, stable disease, and progression. A discount rate of 3% was applied to costs and outcomes. Results The most common alternatives used in Italy for the management of steroid-refractory/resistant cGvHD were ECP, mycophenolate, pentostatin, and imatinib. The literature review highlighted that complete and partial responses are higher with ECP than with the alternatives while serious adverse events are less common. The economic analysis showed that Therakos online ECP represents the dominating alternative, in that it delivers greater benefit at a lower cost. In fact, according to the alternatives considered, cost saving ranged from €3237.09 to €19,903.51 per patient with 0.04 to 0.21 quality-adjusted life-year gained. Conclusions Therakos online ECP should be considered an effective, safe, and cost-effective alternative in steroid-refractory/resistant cGvHD. There is inequality in access, and a dedicated reimbursement tariff, however, should be introduced to overcome these barriers.

Original languageEnglish
Article number1100
Pages (from-to)457-466
Number of pages10
JournalValue in Health
Volume18
Issue number4
DOIs
Publication statusPublished - Jun 1 2015

Keywords

  • cost-effectiveness analysis
  • economic evaluation
  • graft-versus-host disease
  • Markov model
  • photopheresis
  • technology assessment

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health
  • Medicine(all)

Fingerprint Dive into the research topics of 'Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy'. Together they form a unique fingerprint.

Cite this